VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Lab model reveals the formation of new blood vessels

To provide sufficient oxygen to tissues and organs within the body, blood vessels need to sprout new offshoots to form a widespread blood supply network, much like the trunk, branches, and twigs of a tree.

31 Jan 2019

Complex interplay of two growth factors key to fast-acting antidepressant actions

A study by researchers at Yale University reveals a complex interplay of two different growth factors in the rapid and long-lasting antidepressant effects of ketamine.

31 Jan 2019

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

$Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer$

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.

22 Oct 2018

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhea in cancer patients, according to results of a phase II/III study in India.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Immunotherapy medicine found to be effective in treating uveitis

A team of researchers from the UCH CEU's Biomedical Sciences Institute has tested the efficiency of Bevacizumab, medicine used against cancer and in ophtalmology, to treat uveítis, thus stopping the inflammation from spreading.

19 Oct 2018

TGen-UNM consortium awarded NIH grant to discover new treatments for diabetic blindness

Diabetes is an increasing global epidemic that is expected to grow by more than 50 percent in the next two decades, leaving more than half a billion patients worldwide exposed to potentially life-altering medical complications, including pain and numbness in the feet, lost limbs, life-threatening disorders of the heart, liver and kidneys -- and even blindness.

26 Sep 2018

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.

21 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

Many eye diseases, including diabetic retinopathy and macular degeneration, exhibit increased permeability of blood vessels in the macular (central) portion of the retina leading to abnormal fluid accumulation and vision loss.

14 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

Adding another inhibitor to therapies that cut off a tumor's access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer.

27 Aug 2018

Saving sight of millions by making eye injections safe and comfortable

Two eye surgeons have written a first-of-its-kind book to save the sight of millions of patients around the world by making eye injections safe and comfortable.

7 Aug 2018

Scientists move one step further in developing eye drops to treat age-related macular degeneration

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration.

20 Jul 2018

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.

30 Jun 2018

Researchers explore targeted second-line treatment for colorectal cancer

Targeted therapy with anti-VEGF and anti-EGFR antibodies both improve outcomes when added to chemotherapy in the treatment of colorectal cancer. However, some previous studies suggested the combination of the two antibodies may have a negative interaction.

5 Jun 2018

Researchers develop injectable bandage to stop fatal blood loss, activate wound healing

While several products are available to quickly seal surface wounds, rapidly stopping fatal internal bleeding has proven more difficult.

22 May 2018

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.

22 May 2018

Non-aspirin NSAID use linked to shorter survival in patients with metastatic renal cell carcinoma

Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs' promising anti-cancer properties have been highlighted by a growing body of data in recent years.

2 May 2018

VEGF News and Research

Further Reading

Lab model reveals the formation of new blood vessels

Complex interplay of two growth factors key to fast-acting antidepressant actions

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Immunotherapy medicine found to be effective in treating uveitis

TGen-UNM consortium awarded NIH grant to discover new treatments for diabetic blindness

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

Saving sight of millions by making eye injections safe and comfortable

Scientists move one step further in developing eye drops to treat age-related macular degeneration

Ocular Therapeutix resubmits NDA for DEXTENZA

Researchers explore targeted second-line treatment for colorectal cancer

Researchers develop injectable bandage to stop fatal blood loss, activate wound healing

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

Non-aspirin NSAID use linked to shorter survival in patients with metastatic renal cell carcinoma

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News